Alito temporarily restores mifepristone mail access

Justice Alito paused a lower court block on FDA mifepristone mail delivery, giving the Supreme Court more time to weigh the dispute.

A Supreme Court stay from Justice Samuel Alito is buying time for mifepristone access, temporarily restoring an FDA rule that allows the abortion pill to be prescribed via telehealth and delivered by mail.

In an order issued Monday, Alito halted an appellate court ruling that had blocked the FDA policy.. The temporary relief applies while the Supreme Court considers emergency requests from the drugmaker Danco Laboratories and the manufacturer of a generic version. GenBioPro. asking the justices to set aside the appellate decision.. Alito’s administrative stay remains in place until May 11. setting a deadline for Louisiana officials to respond to the companies’ emergency appeals.

This development matters because it directly affects how quickly patients can obtain medication abortion—an issue the courts have repeatedly treated as urgent given the time-sensitive nature of mifepristone care.

The dispute traces back to Louisiana’s challenge to the FDA’s 2023 change allowing mail delivery of mifepristone. after earlier enforcement steps during and after the pandemic loosened in-person requirements.. A federal district court in Louisiana had paused the litigation in April while the FDA reviewed aspects of the safety-and-availability question.. Louisiana appealed to the U.S.. Court of Appeals for the 5th Circuit, which last week agreed to block the 2023 policy.

The 5th Circuit said Louisiana had legal standing to sue. citing the state’s Medicaid program and its role in paying for emergency-room care for women who experienced complications after receiving mifepristone from out of state.. The panel characterized the appellate order as necessary because the FDA’s rule. in its view. undermined Louisiana’s restrictions on abortion and increased the likelihood of state spending on emergency treatment.

From a policy perspective, the case underscores how medication access can become a federal-state flashpoint, with federal FDA rules colliding with state efforts to limit or criminalize abortion-related care.

While the appellate court decision aimed to stop the mail and remote-prescribing framework. the companies argued that the uncertainty created by the order would disrupt treatment plans that depend on timely access.. They also asked the Supreme Court to take up the matter and decide the legal merits. contending that the lower court’s action injected chaos into a process patients and providers have relied on.

The Supreme Court has already addressed related legal questions in prior litigation over mifepristone.. In 2024. the court unanimously rejected a challenge seeking to restrict the drug’s availability. concluding that the plaintiffs did not have the legal right to sue the FDA under the claims presented.. Still. the current case returns the issue to the high court in a different posture. centered on the scope and effect of the FDA’s relaxed access rules and the authority of lower courts to block them.

At the end of the day, Alito’s temporary step is less a final resolution than a controlled pause—one that keeps the national status quo intact while the Supreme Court determines how far lower-court authority should reach in rapidly unfolding disputes over abortion medication access.